Advertisement

Labetalol Injection

[15 February 2017]

Products Affected - Description

Labetalol injection, Akorn
5 mg/mL, 40 mL vial, 1 count (NDC 17478-0420-40)


Labetalol injection, Pfizer
5 mg/mL, 4 mL Carpuject syringe, 10 count (NDC 00409-2339-34)
5 mg/mL, 20 mL vial, 1 count (NDC 00409-2267-20)
5 mg/mL, 40 mL vial, 1 count (NDC 00409-2267-54)

Reason for the Shortage

  • Akorn has labetalol injection on shortage due to increased demand.
  • Pfizer has labetalol injection on shortage due to manufacturing delays.

Available Products

Labetalol injection, Akorn
5 mg/mL, 20 mL vial, 1 count (NDC 17478-0420-20)

Estimated Resupply Dates

  • Akorn has labetalol 5 mg/mL 40 mL vials on back order and the company estimates a release date of late-February 2017.
  • Pfizer has labetalol 5 mg/mL 4 mL Carpuject syringes on back order and the company estimates a release date of late-February 2017. The 20 mL and 40 mL vials are on back order and the company estimates a release date of late-February 2017 for the 20 mL vials and early-April 2017 for the 40 mL vials.

Related Shortages

Updated

February 15, January 27, 2017, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing